Sort
82,697 grants matching “vaccine development”
Leadership for HIV/AIDS Clinical Trials Networks; HIV Prevention Trials Network
$5,673,078Deborah J Donnell · Fred Hutchinson Cancer Research Center · UM1 · FY2012 · AI
NIAID CENTERS OF EXCELLENCE FOR INFLUENZA RESEARCH AND RESPONSE: UNIVERSAL INFLUENZA RESEARCH ACTIVITIES
$5,673,019Scott Hensley · University Of Pennsylvania · N01 · FY2022 · AI
REVERSE-Long COVID: A Multicenter Randomized, Placebo-Controlled Clinical Trial of Immunomodulation (with Baricitinib) for Long COVID Related ADRD
$5,665,215E Wesley Ely · Vanderbilt University Medical Center · R01 · FY2024 · AG
CoVPN 3004 - A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine LOC
$5,663,427Lawrence Corey · Fred Hutchinson Cancer Center · UM1 · FY2022 · AI
Acute HIV-1 Infections Network Core
$5,662,126John Andrew Crump · Duke University · U19 · FY2010 · AI
Cancer Center Support Grant
$5,659,018Wendy K Rathmell · Ohio State University · P30 · FY2025 · CA
Preclinical Studies of Vaccines for Pandemic Influenza
$5,658,387Kanta Subbarao · National Institute Of Allergy And Infectious Diseases · ZIA · FY2010 · AI
Rift Valley Fever Virus MP-12 Vaccine Completion
$5,653,143University Of Texas Medical Br Galveston · UC1 · FY2004 · AI
Core C: Vaccine production and process development
$5,637,003Lauren Carter · University Of Washington · U19 · FY2024 · AI
Advancement of Vaccines and Therapies for Henipaviruses
$5,631,841Christopher Broder · Henry M. Jackson Fdn For The Adv Mil/Med · U19 · FY2023 · AI
A Systems Biology Approach to the Model Apicomplexan Toxoplasma gondii
$5,630,177Kami Kim · Albert Einstein College Of Medicine · RC4 · FY2010 · AI
SURGERY, IMMUNOLOGY AND IMMUNOTHERAPY OF HUMAN CANCER
$5,629,340John Wayne Cancer Institute · P01 · FY2003 · CA
Novel Influenza Biodefense Therapeutic and Prophylactic
$5,628,310Biota Scientific Management · UC1 · FY2004 · AI
Viral Hemorrhagic Fevers: Disease Modeling and Transmission
$5,627,958Heinrich Feldmann · National Institute Of Allergy And Infectious Diseases · ZIA · FY2022 · AI
The UCSD CD4 Collaborative Clinical Trial Unit
$5,626,528Constance Ann Benson · University Of California, San Diego · UM1 · FY2014 · AI
Vaccines and Therapeutics for Anthrax
$5,625,818Stephen H Leppla · Niaid Extramural Activities · Z01 · FY2007 · AI
The J. Craig Venter Institute Genome Center for Infectious Diseases
$5,620,569William Charles Nierman · J. Craig Venter Institute, Inc. · U19 · FY2014 · AI
Leadership Group for the Infectious Diseases Clinical Research Consortium (IDCRCLG)
$5,617,284David S Stephens · Emory University · UM1 · FY2022 · AI
Advancement of Vaccines and Therapies for Henipaviruses
$5,616,110Christopher Broder · Henry M. Jackson Fdn For The Adv Mil/Med · U19 · FY2022 · AI
Delaney AIDS Research Enterprise to Cure HIV
$5,612,699Steven Grant Deeks · University Of California, San Francisco · UM1 · FY2021 · AI
University of North Carolina Global HIV Prevention and Treatment Clinical Trials Unit
$5,609,272Joseph J. Eron · Univ Of North Carolina Chapel Hill · UM1 · FY2021 · AI
A prospective study of critical environmental exposures in formative early life that impact lifelong health in rural US children: the New Hampshire Birth Cohort Study
$5,605,558Margaret Rita Karagas · Dartmouth College · UH3 · FY2019 · OD
Development/Production-Alternative Serotype HIV Recombinant Adenoviral Vaccine
$5,602,987Kimberly Wallace · Niaid Extramural Activities · Z01 · FY2007 · AI
NIAID CENTERS OF EXCELLENCE FOR INFLUENZA RESEARCH AND RESPONSE: UNIVERSAL INFLUENZA RESEARCH ACTIVITIES
$5,602,358Scott Hensley · University Of Pennsylvania · N01 · FY2021 · AI
Development of Proteosome-adjuvanted nasal SARS vaccines
$5,599,999Id Biomedical Corporation Of Washington · UC1 · FY2004 · AI